Seelos Therapeutics selected by U.S. Army to evaluate SLS-002 in PTSD

Seelos Therapeutics signed a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity – USAMMDA – to supply SLS-002 – intranasal racemic ketamine – for the U.S. Department of Defense’s Military and Veterans Adaptive Platform Clinical Trial to evaluate its potential for treatment of post-traumatic stress disorder. Dosing of the SLS-002 cohort is expected to commence prior to the end of 2024. The trial is funded by the DOD’s Defense Health Agency and led by USAMMDA’s Warfighter Readiness, Performance, and Brain Health Project Management Office. The Phase II study that will evaluate the safety, tolerability, and efficacy of multiple pharmacotherapeutic interventions in active-duty service members and veterans with PTSD. Endpoints include the incidence of new or worsening suicidal thoughts or behaviors. In addition, the trial is evaluating several biomarkers associated with PTSD and assessing treatment safety and tolerability.